Total Payments
$1.1M
2024 Payments
$251,524
Companies
49
Transactions
1,884
Medicare Patients
2,083
Medicare Billing
$532,565
Payment Breakdown by Category
Other$635,444 (57.3%)
Consulting$288,782 (26.0%)
Travel$130,414 (11.8%)
Food & Beverage$53,805 (4.8%)
Education$1,195 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $501,878 | 191 | 45.2% |
| Consulting Fee | $288,782 | 147 | 26.0% |
| Travel and Lodging | $130,414 | 432 | 11.8% |
| Honoraria | $112,410 | 61 | 10.1% |
| Food and Beverage | $53,805 | 1,022 | 4.8% |
| Compensation for serving as faculty or as a speaker for a medical education program | $13,750 | 12 | 1.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $7,406 | 12 | 0.7% |
| Education | $1,195 | 7 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Neurocrine Biosciences, Inc. | $261,689 | 217 | $0 (2024) |
| ACADIA Pharmaceuticals Inc | $212,579 | 283 | $0 (2024) |
| MDD US Operations, LLC | $93,707 | 97 | $0 (2024) |
| Abbott Laboratories | $92,859 | 391 | $0 (2024) |
| Amneal Pharmaceuticals LLC | $71,043 | 64 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $60,899 | 77 | $0 (2024) |
| US WorldMeds, LLC | $49,300 | 121 | $0 (2019) |
| Lundbeck LLC | $41,694 | 92 | $0 (2024) |
| UCB, Inc. | $35,710 | 67 | $0 (2024) |
| Kyowa Kirin, Inc. | $33,230 | 27 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $251,524 | 503 | Neurocrine Biosciences, Inc. ($109,597) |
| 2023 | $158,139 | 174 | Neurocrine Biosciences, Inc. ($114,443) |
| 2022 | $63,334 | 98 | Neurocrine BioSciences, Inc. ($18,612) |
| 2021 | $44,502 | 86 | Amneal Pharmaceuticals LLC ($13,059) |
| 2020 | $62,438 | 74 | Sunovion Pharmaceuticals Inc. ($21,287) |
| 2019 | $97,620 | 210 | Kyowa Kirin, Inc. ($21,619) |
| 2018 | $142,315 | 312 | ACADIA Pharmaceuticals Inc ($41,775) |
| 2017 | $289,767 | 427 | ACADIA Pharmaceuticals Inc ($120,610) |
All Payment Transactions
1,884 individual payment records from CMS Open Payments — Page 1 of 76
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Abbott Laboratories | INFINITY (Device) | Food and Beverage | In-kind items and services | $21.28 | General |
| Category: Neuromodulation | ||||||
| 12/30/2024 | Abbott Laboratories | INFINITY (Device) | Food and Beverage | In-kind items and services | $24.92 | General |
| Category: Neuromodulation | ||||||
| 12/19/2024 | Abbott Laboratories | INFINITY (Device) | Travel and Lodging | In-kind items and services | $460.90 | General |
| Category: Neuromodulation | ||||||
| 12/19/2024 | Abbott Laboratories | INFINITY (Device) | Travel and Lodging | In-kind items and services | $435.18 | General |
| Category: Neuromodulation | ||||||
| 12/19/2024 | Abbott Laboratories | INFINITY (Device) | Travel and Lodging | In-kind items and services | $175.77 | General |
| Category: Neuromodulation | ||||||
| 12/19/2024 | Abbott Laboratories | INFINITY (Device) | Travel and Lodging | In-kind items and services | $171.00 | General |
| Category: Neuromodulation | ||||||
| 12/19/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $25.62 | General |
| Category: NEUROLOGY | ||||||
| 12/18/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,450.00 | General |
| 12/18/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $64.99 | General |
| 12/18/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $31.92 | General |
| 12/18/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $29.97 | General |
| 12/18/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $25.92 | General |
| 12/17/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,600.00 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 12/17/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,650.00 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 12/16/2024 | Currax Pharmaceuticals LLC | ONZETRA XSAIL (Drug) | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: Neurology | ||||||
| 12/16/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $5.43 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/13/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 12/12/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: Neuroscience | ||||||
| 12/12/2024 | Abbott Laboratories | INFINITY (Device) | Food and Beverage | In-kind items and services | $13.34 | General |
| Category: Neuromodulation | ||||||
| 12/11/2024 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,550.00 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 12/10/2024 | Amneal Pharmaceuticals LLC | CREXONT (Drug) | Food and Beverage | In-kind items and services | $23.78 | General |
| Category: NEUROLOGY | ||||||
| 12/10/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $23.23 | General |
| Category: NEUROLOGY | ||||||
| 12/10/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $2.55 | General |
| Category: NEUROLOGY | ||||||
| 12/09/2024 | Ipsen Biopharmaceuticals, Inc | Dysport (Drug) | Food and Beverage | In-kind items and services | $23.01 | General |
| Category: Neurology | ||||||
| 12/05/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $49.78 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 596 | 8,720 | $643,397 | $148,837 |
| 2022 | 8 | 557 | 10,080 | $721,001 | $168,125 |
| 2021 | 7 | 486 | 6,823 | $625,580 | $141,644 |
| 2020 | 6 | 444 | 946 | $395,542 | $73,959 |
Total Patients
2,083
Total Services
26,569
Medicare Billing
$532,565
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 155 | 241 | $138,370 | $37,445 | 27.1% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 19 | 7,500 | $120,000 | $37,243 | 31.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 171 | 318 | $135,420 | $34,312 | 25.3% |
| 95984 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | Office | 2023 | 65 | 365 | $119,355 | $14,606 | 12.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 72 | 72 | $57,840 | $12,603 | 21.8% |
| 95983 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | Office | 2023 | 65 | 162 | $54,432 | $7,522 | 13.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 49 | 62 | $17,980 | $5,106 | 28.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 165 | 396 | $169,080 | $43,276 | 25.6% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 21 | 8,700 | $139,200 | $42,620 | 30.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 112 | 186 | $106,522 | $31,220 | 29.3% |
| 95984 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, each additional 15 minutes with qualified health professional | Office | 2022 | 67 | 459 | $149,545 | $19,476 | 13.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 96 | 96 | $77,440 | $18,683 | 24.1% |
| 95983 | Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | Office | 2022 | 67 | 199 | $66,634 | $9,520 | 14.3% |
| 95874 | Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | Office | 2022 | 12 | 24 | $6,960 | $1,890 | 27.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 17 | 20 | $5,620 | $1,439 | 25.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 154 | 355 | $150,610 | $36,574 | 24.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 89 | 179 | $102,140 | $28,689 | 28.1% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 15 | 5,600 | $89,600 | $27,196 | 30.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 115 | 115 | $89,370 | $21,898 | 24.5% |
| 95984 | Electronic analysis of implanted brain, spinal cord or peripheral stimulation device with brain stimulator programming, additional 15 minutes face-to-face time with qualified health care professional | Office | 2021 | 50 | 380 | $124,260 | $16,337 | 13.1% |
| 95983 | Electronic analysis of implanted brain, spinal cord or peripheral stimulation device with brain stimulator programming, first 15 minutes face-to-face time with qualified health care professional | Office | 2021 | 51 | 175 | $58,800 | $8,590 | 14.6% |
| 64616 | Injection of chemical for destruction of nerve muscles on one side of neck excluding voice box accessed through the skin | Office | 2021 | 12 | 19 | $10,800 | $2,360 | 21.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 136 | 266 | $113,540 | $22,545 | 19.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 71 | 135 | $77,040 | $16,562 | 21.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 76 | 76 | $60,840 | $12,970 | 21.3% |
About Dr. Fiona Gupta, M.D
Dr. Fiona Gupta, M.D is a Neurology healthcare provider based in Oradell, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/03/2008. The National Provider Identifier (NPI) number assigned to this provider is 1346409547.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Fiona Gupta, M.D has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $251,524 received in 2024. These payments were reported across 1,884 transactions from 49 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($501,878).
As a Medicare-enrolled provider, Gupta has provided services to 2,083 Medicare beneficiaries, totaling 26,569 services with total Medicare billing of $532,565. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Oradell, NJ
- Active Since 06/03/2008
- Last Updated 09/11/2014
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1346409547
Products in Payments
- INGREZZA (Drug) $236,354
- NUPLAZID (Drug) $212,579
- RYTARY (Drug) $55,924
- AUSTEDO (Drug) $54,694
- APOKYN (Drug) $43,771
- NORTHERA (Drug) $41,137
- Apokyn (Drug) $40,284
- INFINITY (Device) $37,498
- Gocovri (Drug) $36,361
- Neupro (Drug) $35,556
- GOCOVRI (Drug) $30,578
- NOURIANZ (Drug) $25,254
- Infinity DBS Pulse Generators (Device) $21,821
- LATUDA (Drug) $21,287
- Neuromodulation Dspsbls and Accs (Device) $17,777
- Xadago (Drug) $17,455
- ONGENTYS (Drug) $13,116
- XEOMIN (Biological) $11,715
- Duopa (Drug) $9,385
- INBRIJA (Drug) $9,357
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.